Risk of ischemic heart disease in women after radiotherapy for breast cancer by Darby, Sarah C et al.
n engl j med 368;11 nejm.org march 14, 2013 987
The new england 
journal of medicine
established in 1812 march 14, 2013 vol. 368 no. 11
Risk of Is che mic Heart Disease in Women after Radiotherapy 
for Breast Cancer
Sarah C. Darby, Ph.D., Marianne Ewertz, D.M.Sc., Paul McGale, Ph.D., Anna M. Bennet, Ph.D.,  
Ulla Blom-Goldman, M.D., Dorthe Brønnum, R.N., Candace Correa, M.D., David Cutter, F.R.C.R.,  
Giovanna Gagliardi, Ph.D., Bruna Gigante, Ph.D., Maj-Britt Jensen, M.Sc., Andrew Nisbet, Ph.D.,  
Richard Peto, F.R.S., Kazem Rahimi, D.M., Carolyn Taylor, D.Phil., and Per Hall, Ph.D.
A bs tr ac t
From the Clinical Trial Service Unit 
(S.C.D., P.M., D.C., R.P., C.T.) and the 
George Centre for Healthcare Innovation 
(K.R.), University of Oxford, Oxford, and 
the Department of Medical Physics, Royal 
Surrey County Hospital and Surrey Univer-
sity, Guildford (A.N.) — both in the Unit-
ed Kingdom; the Department of Oncolo-
gy, Odense University Hospital, Institute 
of Clinical Research, University of South-
ern Denmark, Odense (M.E.), the Oncol-
ogy Department, Aalborg Hospital, Aal-
borg (D.B.), and the Danish Breast 
Cancer Cooperative Group, Rigshospi-
talet, Copenhagen (M.-B.J.) — all in Den-
mark; the Department of Medical Epide-
miology and Biostatistics (A.M.B., P.H.) 
and the Division of Cardiovascular Epide-
miology, Institute of Environmental Med-
icine and Division of Cardiovascular 
Medicine, Department of Clinical Sci-
ences, Danderyd Hospital (B.G.), Karolin-
ska Institutet, and the Departments of 
Oncology (U.B.-G.) and Medical Physics 
(G.G.), Karolinska University Hospital — 
all in Stockholm; and the H. Lee Moffitt 
Cancer Center and Research Institute, 
University of Southern Florida, Tampa 
(C.C.). Address reprint requests to Dr. 
Darby at the Clinical Trial Service Unit, 
Richard Doll Bldg., Old Road Campus, 
Oxford OX3 7LF, United Kingdom, or at 
sarah.darby@ctsu.ox.ac.uk.
N Engl J Med 2013;368:987-98.
DOI: 10.1056/NEJMoa1209825
Copyright © 2013 Massachusetts Medical Society.
Background
Radiotherapy for breast cancer often involves some incidental exposure of the heart 
to ionizing radiation. The effect of this exposure on the subsequent risk of is che mic 
heart disease is uncertain.
Methods
We conducted a population-based case–control study of major coronary events (i.e., 
myocardial infarction, coronary revascularization, or death from is che mic heart 
disease) in 2168 women who underwent radiotherapy for breast cancer between 
1958 and 2001 in Sweden and Denmark; the study included 963 women with major 
coronary events and 1205 controls. Individual patient information was obtained 
from hospital records. For each woman, the mean radiation doses to the whole heart 
and to the left anterior descending coronary artery were estimated from her radio-
therapy chart.
Results
The overall average of the mean doses to the whole heart was 4.9 Gy (range, 0.03 to 
27.72). Rates of major coronary events increased linearly with the mean dose to the 
heart by 7.4% per gray (95% confidence interval, 2.9 to 14.5; P<0.001), with no ap-
parent threshold. The increase started within the first 5 years after radiotherapy 
and continued into the third decade after radiotherapy. The proportional increase 
in the rate of major coronary events per gray was similar in women with and 
women without cardiac risk factors at the time of radiotherapy.
Conclusions
Exposure of the heart to ionizing radiation during radiotherapy for breast cancer 
increases the subsequent rate of is che mic heart disease. The increase is propor-
tional to the mean dose to the heart, begins within a few years after exposure, and 
continues for at least 20 years. Women with preexisting cardiac risk factors have 
greater absolute increases in risk from radiotherapy than other women. (Funded by 
Cancer Research UK and others.)
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Randomized trials have shown that radiotherapy for early-stage breast cancer can reduce the rates of recurrence and of 
death from breast cancer.1,2 However, long-term 
follow-up in some trials has shown that radio-
therapy can also increase the risk of is che mic 
heart disease, presumably through incidental ir-
radiation of the heart.1,3
Radiotherapy regimens for breast cancer 
have changed since the women in these trials 
were irradiated, and the doses of radiation to 
which the heart is exposed are now generally 
lower.4 Nevertheless, in most women, the heart 
still receives doses of 1 to 5 Gy.5-11 Several stud-
ies have suggested that exposures at this level 
can cause is che mic heart disease,12-14 but the 
magnitude of the risk after any given dose to the 
heart is uncertain, as are the time to the devel-
opment of any radiation-related disease and the 
influence of other cardiac risk factors. We there-
fore conducted a study relating the risk of is che-
mic heart disease after radiotherapy to each 
woman’s radiation dose to the heart and to any 




A population-based case–control study of major 
coronary events was conducted in women in Swe-
den and Denmark who received external-beam 
radiotherapy for invasive breast cancer. Major 
coronary events were defined as a diagnosis of 
myocardial infarction (International Classification of 
Diseases, 10th Revision [ICD-10] codes I21–I24), 
coronary revascularization, or death from is che-
mic heart disease (ICD-10 codes I20–I25). Patients 
with a diagnosis of angina alone were not includ-
ed, because pilot studies showed that we could 
not reliably identify angina. Patient records from 
hospital oncology departments were used to ob-
tain data on each woman’s medical history be-
fore her diagnosis of breast cancer, tumor char-
acteristics, and radiotherapy.
Eligibility Criteria
A single study protocol was used, but the selec-
tion of case patients and controls varied slightly 
between the two countries. In Sweden, all wom-
en living in Stockholm for whom data were re-
corded in the Swedish National Cancer Register15 
were considered for the study if they received a 
diagnosis of breast cancer between 1958 and 
2001, were younger than 70 years of age at the 
time of diagnosis, and had received radiotherapy. 
Because information on radiotherapy is not kept 
by the Swedish Register, hospital records were 
used to determine which women had received ra-
diotherapy. In Denmark, all women for whom 
data were recorded in the register held by the 
Danish Breast Cancer Cooperative Group16 were 
considered for the study if they received the diag-
nosis of breast cancer between 1977 and 2000, 
were younger than 75 years at the time of diag-
nosis, and received radiotherapy. The study was 
approved by the Danish Data Protection Agency 
and by the ethics review board of the Karolinska 
Institutet in Stockholm. The requirement for in-
formed consent was waived because of the nature 
of the study.
In both countries, women without histopatho-
logical confirmation of breast cancer, with bilat-
eral or metastatic disease at the time of diagnosis, 
or with a history of cancer (excluding nonmela-
noma skin cancer) or previous radiotherapy to 
the thoracic area were excluded. All other women 
who received radiotherapy were cross-matched 
with nationwide registers of diagnosis at the time 
of hospital discharge and cause of death (up to 
2002 in Sweden and 2007 in Denmark).17 Women 
whose primary diagnosis was a major coronary 
event that occurred after a diagnosis of breast 
cancer but before any recurrence or diagnosis of 
a second cancer were classified as case patients. 
Whenever possible, hospital cardiology or autopsy 
records were reviewed, and if the case-defining 
event was refuted, the woman was excluded from 
the study. For each remaining case patient, we 
defined “time period” as the time from breast-
cancer diagnosis to the time of first major coro-
nary event. Controls (one per case patient in 
Sweden and two per case patient in Denmark) 
were selected at random from all eligible women 
in the study population. Eligibility criteria for 
controls included fulfillment of the matching 
criteria (country of residence, age at the time of 
breast-cancer diagnosis, and year of diagnosis, 
with both age and year matched within 5 years); 
receipt of radiotherapy; and no recurrence of 
breast cancer, no diagnosis with another cancer, 
and no major coronary event before the index 
date (defined as the date of breast-cancer diag-
nosis plus the time period of the matched case).
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Radiation Dosimetry
Individual radiotherapy charts, including a diagram 
or photograph of the treatment fields and a dose 
plan (where available) were copied. Virtual simu-
lation and planning based on computed tomog-
raphy (CT) (or, for a few regimens, manual plan-
ning) were used to reconstruct each radiotherapy 
regimen on the CT scan of a woman with typical 
anatomy. Virtual simulation and CT planning in-
volved the reconstruction of radiotherapy fields 
on a CT scan. Radiation doses to the structures 
of interest were then estimated with the use of 
the treatment-planning system Helax–TMS, ver-
sion 6.1B (Nucletron). In manual planning, the 
doses were estimated on the basis of charts on 
which isodose curves (i.e., lines delimiting areas 
receiving the same radiation dose) had been 
drawn. As previously described,18,19 dose-volume 
histograms for the whole heart and for the left 
anterior descending coronary artery (which of-
ten receives the highest dose of radiation from 
radiotherapy for cancer of the left breast) were 
obtained for the regimens used, and the mean 
doses received by these two structures were cal-
culated. Equivalent doses  delivered in 2-Gy frac-
tions (EQD2)20 were cal culated from the dose-
volume histograms as nd[(d+α/β)÷(2+α/β)], where 
n was the number of fractions, d was the dose to 
the heart per fraction (in Gy), and α/β was 2 Gy.21
Statistical Analysis
Rate ratios were estimated with the use of condi-
tional logistic regression after stratification ac-
cording to country and to age at the time of can-
cer diagnosis, year of cancer diagnosis, and years 
from cancer diagnosis to first subsequent major 
coronary event (for case patients) or the index 
date (for controls) (all in 5-year categories).22,23 
To estimate the proportional increase in the rate 
of major coronary events per gray of radiation, the 
data were also stratified according to presence or 
absence of a cardiac risk factor. The rate of major 
coronary events was modeled as Bs(1+KX), where 
Bs was the stratum-specific rate of major coro-
nary events in the absence of radiotherapy, X was 
the dose (or EQD2) of cardiac radiation (in Gy), 
and K was the percentage increase in the rate of 
major coronary events per gray. The form 1+KX 
was chosen for the dose–response relationship 
because a wide variety of functions are approxi-
mately linear for small values of X. The adequacy 
of 1+KX for summarizing the dose–response re-
lationship was examined by carrying out analyses 
based on categories of radiation dose. In these 
analyses and in tests for interactions between ra-
diation dose and other factors, models similar to 
the model described above were used. Signifi-
cance tests were two-sided, and both signifi-
cance tests and confidence intervals were based 
on the likelihood ratio. For analyses in which the 
explanatory variable was categorical, the confi-
dence intervals for every category, including the 
reference category, were estimated from the 
amount of information in that category.24 Calcu-
lations were performed with the use of Stata Sta-
tistical Software, release 12 (StataCorp),25 and 
EpiWin, release 1.8 (Hirosoft International).26
R esult s
Characteristics of the Patients
A total of 963 women with major coronary events 
and 1205 controls were included in the study. 
Among the case-defining major coronary events 
(i.e., the event resulting in inclusion in the study), 
44% occurred less than 10 years after breast can-
cer was diagnosed, 33% occurred 10 to 19 years 
afterward, and 23% occurred 20 or more years 
afterward. Hospital cardiology or autopsy re-
cords confirmed the case-defining major coro-
nary event in 65% of case patients and were con-
sistent with the event in 9% of case patients; for 
the remaining 26% of case patients, no relevant 
record could be found. A total of 54% of case pa-
tients were known to have died from is che mic heart 
disease, either at the time of their case-defining 
event or subsequently. (For further information, 
see Tables S1, S2, and S3 in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org.)
Risk Factors for a Major Coronary Event
Women irradiated for cancer of the left breast 
had higher rates of major coronary events than 
women irradiated for cancer of the right breast 
(P = 0.002), but there were no other strong associa-
tions between the rate of major coronary events 
and tumor characteristics or the cancer treat-
ments administered in addition to radiotherapy 
(rate ratio, 1.20; P = 0.06 for nodal status and 
P≥0.10 for all other tumor or treatment charac-
teristics) (Table 1). In contrast, the overall rate 
ratio for a major coronary event among women 
with a history of is che mic heart disease as com-
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Table 1. Characteristics of the Women in the Study at the Time of Breast-Cancer Diagnosis and Association between the Characteristics 
and the Subsequent Rate of Major Coronary Events.*
Characteristic
No. of Case Patients 
(N = 963)
No. of Controls 
(N = 1205) Rate Ratio P Value†
Tumor characteristics
Nodal status 0.06
Negative 482 610 1.00
Positive 463 579 1.20
Unknown 18 16 0.96
Size 0.97
<2 cm 331 449 1.00
2–5 cm 494 604 1.00
Other or unknown 138 152 1.08
Location 0.22
Outer quadrants 350 572 1.00
Inner quadrants 114 204 0.84
Other or unknown 499 429 0.82
Laterality of breast cancer 0.002
Right 420 604 1.00
Left 543 601 1.32
Cancer treatment
Surgery 0.22
Mastectomy 748 860 1.00
Breast-conserving surgery 212 337 0.86
None 3 8 0.39
Adjuvant hormonal therapy‡ 0.10
No 732 892 1.00
Yes 229 311 1.23
Unknown 2 2 0.80
Adjuvant chemotherapy§ 0.13
No 889 1057 1.00
Yes 74 148 0.73
Ovarian ablation¶ 0.54
No 774 1027 1.00
Yes 70 89 0.89
Unknown 119 89 1.54
Factors associated with subsequent coronary event <0.001
No known cardiac risk factors 353 600 1.00
History of is che mic heart disease‖ 109 38 6.67**
Risk factors other than is che mic heart disease†† 458 527 1.96**
Unknown 43 40 1.23
History of circulatory disease other than is che mic heart disease‡‡ <0.001
No 536 845 1.00
Yes 265 269 1.88
Unknown 53 53 1.04
History of diabetes§§ <0.001
No 704 1056 1.00
Yes 55 29 3.23
Unknown 95 82 1.19
History of COPD§§ <0.001
No 736 1076 1.00
Yes 15 6 6.33
Unknown 103 85 1.24
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Table 1. (Continued.)
Characteristic
No. of Case Patients 
(N = 963)
No. of Controls 
(N = 1205) Rate Ratio P Value†
Current smoker§§ <0.001
No 160 344 1.00
Yes 167 195 1.87
Unknown 527 628 1.39
BMI§§ 0.002
<30 321 574 1.00
≥30 139 165 1.57
Unknown 394 428 1.00
Analgesic medication§§ 0.02
No 509 836 1.00
Yes 50 54 1.65
Unknown 295 277 1.01
Other medications
Hormone-replacement therapy 0.006
No 495 731 1.00
Yes 79 178 0.66
Unknown 389 296 1.70
Thyroid medication 0.60
No 635 888 1.00
Yes 26 37 0.87
Unknown 302 280 0.90
Other medications¶¶ 0.08
No 740 958 1.00
Yes 38 70 0.69
Unknown 185 177 0.84
*  The category listed first is the baseline category. Rate ratios were estimated after stratification according to country and age at breast-cancer 
diagnosis, year of breast-cancer diagnosis, and years from breast-cancer diagnosis to first subsequent major coronary event (for case pa-
tients) or index date (for controls) (all in 5-year categories). BMI denotes body-mass index (the weight in kilograms divided by the square 
of the height in meters).
† The test for heterogeneity between categories did not include the categories of “unknown” or “other or unknown.”
‡  Adjuvant hormonal therapy consisted of tamoxifen in 197 case patients and 258 controls, an aromatase inhibitor in 6 case patients and  
16 controls, and another medication in 26 case patients and 37 controls.
§  Chemotherapy consisted of cyclophosphamide, methotrexate, and fluorouracil in 44 case patients and 105 controls; an anthracycline-
based regimen in 8 case patients and 9 controls; and other chemotherapy (but without an anthracycline) in 22 case patients and 34 controls.
¶  For 34 case patients and 55 controls, ovarian ablation consisted of oophorectomy before the diagnosis of breast cancer.
‖  Women with a history of is che mic heart disease were defined as those for whom myocardial infarction or angina had been cited in their 
oncology record at the time of breast-cancer diagnosis or for whom is che mic heart disease had been recorded as a primary diagnosis in 
the hospital discharge register before the breast-cancer diagnosis.
**  These rate ratios can be subdivided according to the time since breast-cancer diagnosis. Rate ratios for major coronary events in women 
with a history of is che mic heart disease up to 10 years and 10 or more years after breast-cancer diagnosis were 13.43 (95% confidence inter-
val [CI], 7.65 to 23.58) and 2.09 (95% CI, 1.05 to 4.13), respectively (P<0.001). Rate ratios for major coronary events in women without a his-
tory of is che mic heart disease but with other cardiac risk factors for up to 10 years and for 10 years or more after the breast-cancer diag-
nosis were 2.60 (95% CI, 1.89 to 3.57) and 1.63 (95% CI, 1.24 to 2.15), respectively (P = 0.03). See Table S4 in the Supple men tary 
Appendix for further details.
††  The factors associated with a subsequent risk of heart disease in women without a history of is che mic heart disease included factors for 
which the association was likely to be causal (e.g., current smoker) and factors for which the association was indirect (e.g., history of 
chronic obstructive pulmonary disease).
‡‡  This category excludes 109 case patients and 38 controls who had a history of is che mic heart disease (as defined above) and indicates 
which of the remaining women who, before their diagnosis of breast cancer, had received a primary diagnosis of circulatory disease 
(International Classification of Diseases, 10th Revision, codes I-00 to I-15 or I-26 to I-99), according to the hospital discharge register, or had 
received medication for cardiac disease or hypertension according to their oncology record.
§§  This category excludes 109 case patients and 38 controls who had a history of ischemic heart disease (as defined above) and indicates 
which of the remaining women appeared in the hospital discharge register with this condition as a primary diagnosis before breast-cancer 
diagnosis or had an oncology record in which this factor was cited.
¶¶  This category excludes women who at the time of their diagnosis were receiving medication for cardiac disease or hypertension or an analge-
sic medication, according to the oncology record.
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pared with women with no such history was 6.67 
(95% confidence interval [CI], 4.37 to 10.18). The 
rate ratio was 13.43 (95% CI, 7.65 to 23.58) dur-
ing the first 10 years after the cancer diagnosis 
as compared with 2.09 (95% CI, 1.05 to 4.13) 
during later years (P<0.001) (Table S4 in the Sup-
plementary Appendix). Rates of major coronary 
events were also elevated among women with a 
history of other circulatory diseases, diabetes, or 
chronic obstructive pulmonary disease; among 
women who smoked; and among women with a 
high body-mass index or a history of regular an-
algesic use. The rate ratio for the presence of one 
or more of these factors but no is che mic heart 
disease was 1.96 overall (95% CI, 1.60 to 2.40); 
during the first 10 years after the cancer diagno-
sis, the rate ratio was 2.60 (95% CI, 1.89 to 3.57) 
as compared with 1.63 (95% CI, 1.24 to 2.15) 
during later years (P = 0.03).
Effect of Radiotherapy
The overall average of the estimated mean doses 
of radiation to the heart was 6.6 Gy for women 
with tumors in the left breast, 2.9 Gy for those 
with tumors in the right breast, and 4.9 Gy over-
all (range, 0.03 to 27.72). The rate of major coro-
nary events increased by 7.4% for each increase 
of 1 Gy in the mean radiation dose delivered to 
the heart (95% CI, 2.9 to 14.5; P<0.001) (Fig. 1). 
When women were grouped according to wheth-
er the mean radiation dose to the heart was less 
than 2 Gy, 2 to 4 Gy, 5 to 9 Gy, or 10 or more Gy, 
the percentage increases in the rate of major cor-
onary events in these four categories, as com-
pared with the estimated rate if the cardiac dose 
had been zero, were 10% (95% CI, −9 to 33), 30% 
(95% CI, 14 to 49), 40% (95% CI, 15 to 72), and 
116% (95% CI, 59 to 195), respectively. The per-
centage increase per gray did not differ signifi-
cantly according to any of the matching factors 
used in the selection of controls, tumor charac-
teristics (including whether the tumor was in the 
left or right breast), or cancer treatments in addi-
tion to radiotherapy. Despite the fact that the rate 
of major coronary events was higher among 
women with cardiac risk factors than among 
those without such risk factors, the percentage 
increase in the rate of major coronary events per 
gray was similar for women with and those with-
out a cardiac risk factor at the time of breast-can-
cer diagnosis (Table 2).
Variation with Time since Exposure
The percentage increases in the rate of major coro-
nary events per gray of radiation according to the 
number of years since radiation exposure were as 
follows: 0 to 4 years, 16.3% (95% CI, 3.0 to 64.3); 
5 to 9 years, 15.5% (95% CI, 2.5 to 63.3); 10 to 19 
years, 1.2% (95% CI, −2.2 to 8.5); and 20 or more 
years, 8.2% (95% CI, 0.4 to 26.6) (Table 3). The 
variation among these values was consistent with 
random variation (P = 0.16 for heterogeneity; 
P = 0.26 for trend). Findings were similar when 
the analysis was repeated separately according to 
age at the time of the breast-cancer diagnosis, the 
presence or absence of preexisting cardiac risk 
factors, whether the case patient had died from 
is che mic heart disease, and whether the case pa-
tient’s hospital cardiology record or autopsy re-
cord had been reviewed (Tables S5 through S8 in 
the Supplementary Appendix).
Other Measures of Dose
The overall average of the mean EQD2 doses to 
the heart was 3.9 Gy (range, 0.1 to 30.4). The mean 
doses and the EQD2 doses to the heart were highly 
correlated (correlation coefficient, 0.98). The results 
of analyses based on dose and EQD2 dose were 
therefore similar (Fig. S1 in the Supplementary 
Appendix). Estimated mean doses to the left an-
terior descending coronary artery and to the heart 
were also correlated (correlation coefficient, 0.76) 
(Table S9 in the Supplementary Appendix). The 
mean dose of radiation to the heart was a better 
predictor of the rate of major coronary events 
than the mean dose to the left anterior descend-
ing coronary artery (P<0.001 for mean dose to the 
heart; P = 0.001 for mean dose to the left anterior 
descending coronary artery). The mean dose of 
radiation to the heart remained significantly as-
sociated with the rate of major coronary events 
after the mean dose to the left anterior descending 
coronary artery was taken into account (P = 0.04). 
However, the converse did not apply: the mean 
dose to the left anterior descending coronary ar-
tery was not significantly associated with the rate 
of major coronary events after the mean dose to 
the heart was taken into account (P = 0.62).
Discussion
Breast cancer is the most common cancer in 
women worldwide, with more than 1 million new 
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diagnoses each year.27 Moreover, every year, tens 
of thousands of women worldwide receive a diag-
nosis of ductal carcinoma in situ. The overall 
5-year survival rate for these two diagnostic 
groups combined is approximately 90%, and in 
both groups many of the survivors will have re-
ceived radiotherapy.28 Current mean doses of ra-
diation to the heart from radiotherapy for breast 
cancer are typically about 1 or 2 Gy for disease of 
the right breast. For disease of the left breast, the 
doses are usually higher but vary widely, and for 
some women, including those in whom the dis-
tance of the heart to the thoracic wall is small 
and those who require internal mammary irra-
diation, the mean dose may be around 10 Gy.5-11
Among the 2168 women in this study, the 
mean dose to the heart ranged from 0.03 Gy to 
27.72 Gy, with an overall average of the mean 
doses of 4.9 Gy. The risk of a major coronary 
event increased linearly with the mean dose to 
the heart. The magnitude of the risk was 7.4% 
per gray, with no apparent threshold below 
which there was no risk. The risk started to in-
crease within the first 5 years after exposure and 
continued for at least 20 years. The percentage in-
crease in risk per gray was similar for women 
with and those without cardiac risk factors at the 
time of radiotherapy.
A strength of this study is that it relates the 
risk of is che mic heart disease among women who 
have received radiotherapy for breast cancer to 
individual doses of cardiac radiation and individ-
ual cardiac risk factors at the time of their can-
cer diagnosis. Other strengths of the study are 
that it was carried out in women with cancer 
that had not recurred (thus avoiding confusion 
with the influence of further treatment); that it 
was population-based, including all women re-
corded as receiving radiotherapy for breast cancer 
in Denmark or Stockholm during the period of 
interest (thus avoiding the tendency in random-
ized trials to omit patients in poor health); and 
that the majority of cardiac events were con-
firmed by a review of cardiology or autopsy re-
cords. Because health status may play a role in the 
selection of women for radiotherapy, we includ-
ed in the study only women who had received 
radiotherapy; nonrandomized comparisons of 
women who underwent irradiation with those 
who did not could produce misleading estimates 
of risk.29
A limitation of our study was that individual 
CT-based information on radiotherapy was un-
available for the women studied, because they were 
treated before the era of three-dimensional CT-
based planning. However, we have used 20 con-
secutive individual CT-based, three-dimensional 
planning scans to show that for left and right 
tangential radiotherapy and for left and right 
direct internal mammary fields, the patient-to-
patient variation in mean radiation dose to the 
heart is small (coefficients of variation, 30%, 11%, 
11%, and 21%, respectively).4 We have also con-
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Figure 1. Rate of Major Coronary Events According to 
Mean Radiation Dose to the Heart, as Compared with the 
Estimated Rate with No Radiation Exposure to the Heart.
Major coronary events included myocardial infarction, 
coronary revascularization, and death from is che mic 
heart disease. The values for the solid line were calculat-
ed with the use of dose estimates for individual women. 
The circles show values for groups of women, classified 
according to dose categories; the associated vertical 
lines represent 95% confidence intervals. All estimates 
were calculated after stratification for country and for age 
at breast-cancer diagnosis, year of breast-cancer diagno-
sis, interval between breast-cancer diagnosis and first 
major coronary event for case patients or index date for 
controls (all in 5-year categories), and presence or ab-
sence of a cardiac risk factor. The radiation categories 
were less than 2, 2 to 4, 5 to 9, and 10 Gy or more, and 
the overall averages of the mean doses to the heart of 
women in these categories were 1.4, 3.4, 6.5, and 15.8 Gy, 
respectively.
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was used to calculate the dose estimates in this 
study was average in terms of the radiation dose to 
her heart. Consideration of irradiated structures 
within the heart30,31 may prove fruitful in the 
future, but in the present study, inclusion of the 
estimated mean dose to the left anterior descend-
ing coronary artery did not improve prediction 
of the rate of major coronary events.
Since our study included few women who were 
younger than 40 years of age at the time of radio-
therapy, caution is needed in applying our results 
to women in this age group, and the possibility 
of larger increases in the rate of major coronary 
events per gray of radiation for this group cannot 
be ruled out. Few women in this study were treated 
with anthracyclines, and none with taxanes or 
tras tuz umab, all of which are known to affect the 
heart, even in the absence of radiotherapy.32
Table 2. Radiation Dose to the Heart and Percentage Increase in the Rate of Major Coronary Events per Gray, According to Risk Factors 
and Other Characteristics.*
Characteristic Radiation Dose to Heart
Increase in Rate of Major  
Coronary Events (95% CI)†
P Value  
for Heterogeneity‡
Gy % increase/Gy
Characteristics used for selection of matched controls§
Country 0.38
Sweden 5.4±5.7 5.7 (1.2 to 13.7)
Denmark 4.4±2.7 11.2 (2.5 to 30.7)
Age at diagnosis of breast cancer (yr) 0.99
20–39 4.7±4.8 −1.5 (<−25.3 to 616)
40–49 4.9±4.8 6.3 (−2.0 to 41.3)
50–59 5.1±4.8 7.1 (0.4 to 22.2)
60–69 4.8±4.2 7.8 (1.7 to 19.7)
70–74 4.9±3.1 9.7 (−2.9 to 116)
Year of breast-cancer diagnosis 0.13
1958–1969 3.7±4.1 6.6 (−0.2 to 20.7)
1970–1979 7.3±6.3 20.4 (5.4 to 79.2)
1980–1989 4.9±3.6 0.8 (−2.8 to 8.7)
1990–2001 4.2±2.7 11.8 (−0.1 to 56.2)
Tumor characteristics
Nodal status 0.26
Negative 4.8±4.4 4.0 (−1.0 to 14.1)
Positive 5.0±4.3 11.8 (2.7 to 33.6)
Size 0.24
<2 cm 4.9±4.2 20.4 (3.6 to 98.3)
2–5 cm 4.9±4.5 6.9 (1.1 to 18.0)
Location 0.17
Outer quadrants 4.4±2.8 10.0 (1.1 to 32.8)
Inner quadrants 4.8±3.5 −2.1 (<−6.9 to 21.2)
Laterality of breast cancer 0.88
Right 2.9±2.5 5.0 (−2.2 to 22.5)
Left 6.6±4.9 4.1 (−0.4 to 13.8)
The New England Journal of Medicine 
Downloaded from nejm.org on February 13, 2017. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
R adiother apy and Risk of Heart Disease
n engl j med 368;11 nejm.org march 14, 2013 995
Table 2. (Continued.)
Characteristic Radiation Dose to Heart
Increase in Rate of Major  
Coronary Events (95% CI)†





Mastectomy 5.1±4.7 8.7 (3.2 to 18.0)
Breast-conserving surgery 4.3±3.1 14.9 (−0.1 to 77.6)
Adjuvant hormonal therapy 0.55
No 5.0±4.7 10.0 (3.9 to 20.4)
Yes 4.7±3.4 5.2 (−2.1 to 29.0)
Adjuvant chemotherapy 0.47
No 5.0±4.5 7.6 (2.9 to 15.2)
Yes 4.6±3.3 −0.4 (<−6.7 to 70.2)
Ovarian ablation 0.94
No 4.9±4.2 5.5 (1.1 to 12.9)
Yes 4.3±4.2 6.5 (<−3.6 to 77.7)
Factors associated with subsequent major coronary event¶ 0.99
No 5.1±4.7 7.4 (1.8 to 17.8)
Yes 4.9±4.1 7.4 (1.1 to 19.5)
Other medications‖ 0.58
No 4.8±4.1 8.4 (1.9 to 21.3)
Yes 4.7±3.6 2.8 (−4.3 to 47.3)
Death of case patient from is che mic heart disease** 0.81
No 4.9±4.2 8.0 (2.3 to 17.2)
Yes 4.9±4.5 7.2 (2.4 to 14.9)
Cardiology record of case patient reviewed†† 0.60
No 4.5±3.1 9.2 (1.8 to 21.7)
Yes 5.1±4.8 7.0 (2.5 to 14.2)
All women 4.9±4.4 7.4 (2.9 to 14.5)
*  Radiation doses to the heart are arithmetic averages of mean doses to the whole heart for cases and controls combined, with standard de-
viations.
†  Rates were estimated after stratification according to country, age at breast-cancer diagnosis, year of breast-cancer diagnosis, and years from 
breast-cancer diagnosis to first major coronary event (for case patients) or index date (for controls) (in 5-year categories), the presence or 
absence of a cardiac risk factor, and the characteristic under examination.
‡  P values are based on tests for heterogeneity between the percentage increases in the rate of major coronary events per gray of radiation for 
the categories listed for each characteristic.
§  The numbers of women in each category for the variables used as the basis of selection are listed in Table S2 in the Supplementary Appendix.
¶ Women for whom information about cardiac risk factors was unavailable were classified as not having the risk factors.
‖ This category includes medications other than those prescribed for cardiac disease or hypertension and analgesic medications.
**  “Yes” indicates case patients for whom is che mic heart disease was known to be the underlying cause of death and their matched controls. 
“No” indicates case patients for whom it was not the underlying cause of death and their matched controls.
††  “Yes” indicates case patients for whom a hospital cardiology or autopsy record was reviewed and was found to confirm or to be consistent 
with the case-defining event and their matched controls. “No” indicates case patients for whom no information was available for cardiology re-
view and their matched controls.
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Studies comparing rates of cardiac disease 
among women who received radiotherapy for 
cancer of the left breast and women who re-
ceived radiotherapy for cancer of the right breast 
have been reviewed elsewhere.33-35 Such studies 
are likely to underestimate the extent of any 
radiation-related risk because they rely on any 
difference in cardiac dose between women ir-
radiated for tumors in the left breast and those 
irradiated for tumors in the right breast. In ad-
dition, these studies have generally not had in-
formation on whether a woman had prior heart 
disease, and thus could not account for any ten-
dency to avoid irradiation in women with preex-
isting cardiac risk factors and cancer of the left 
breast or for the exclusion of women whose only 
diagnosis was angina (which may be unreliably 
recorded in routine records). In our study, the 
radiation-related increase in the risk of major 
coronary events began within the first 5 years 
after exposure. Early increases in risk have been 
reported in studies of patients with Hodgkin’s 
lymphoma who received radiotherapy.36-38 The 
effect of preexisting cardiac risk factors on the 
risk of radiation-related is che mic heart disease 
has not been well studied, but one report on 
patients with breast cancer indicated that the 
absolute effect of radiotherapy was greater in 
smokers than in nonsmokers.39 Several studies 
have empirically investigated the relationship 
between cardiac radiation dose and risk of heart 
disease (Table S10 in the Supplementary Appen-
dix). The estimates vary considerably, but this is 
to be expected, since both the populations stud-
ied and the end points reported were diverse.
The relevance of our findings to a woman 
receiving radiotherapy for breast cancer today is 
that they make it possible to estimate her abso-
lute risk of radiation-related is che mic heart dis-
ease. This absolute risk can be weighed against 
the probable absolute reduction in her risk of 
recurrence or death from breast cancer that 
would be achieved with radiotherapy.2 The per-
centage increases in risk per unit increase in the 
mean dose of radiation to the heart are similar 
for women with and women without preexisting 
cardiac risk factors. Therefore, absolute radiation-
related risks are greater for women with preex-
isting cardiac risk factors than for other women. 
Data from a case–control study do not by 
themselves permit estimation of absolute risks. 
Therefore, we have illustrated our results on the 
risk of fatal is che mic heart disease by combining 
them with recent data on rates of death from is-
che mic heart disease for the 15 westernmost 
countries of the European Union combined (Table 
S11 in the Supplementary Appendix). We have 
also illustrated the effect of radiotherapy for breast 
cancer on the risk of an acute coronary event 
(i.e., a major coronary event or unstable angina) 
by assuming that for women younger than 50 
years of age, those 50 to 59 years of age, those 
60 to 69 years of age, and those 70 to 79 years 
of age, the rates of acute coronary events are 6 
times, 5 times, 3 times, and 2 times the rates of 
death from is che mic heart disease, respectively.40 
The resulting baseline lifetime risk estimates are 
similar to recent estimates for the United States.41 
For a 50-year-old woman with no preexisting 
cardiac risk factors, radiotherapy involving a 
mean dose to the heart of 3 Gy would increase her 
risk of death from is che mic heart disease before 
the age of 80 years from 1.9% to 2.4% (i.e., an 
absolute increase of about 0.5 percentage points), 
and it would increase her risk of having at least 
one acute coronary event from 4.5% to 5.4% (i.e., 
an absolute increase of about 0.9 percentage 
points) (Fig. 2). If her mean cardiac dose were 
10 Gy, her absolute risk of death from is che mic 
heart disease would increase from 1.9% to 3.4% 
(1.5 percentage points), and her absolute risk of 
having at least one acute coronary event would in-
crease from 4.5% to 7.7% (3.2 percentage points). 
For women with one or more preexisting car-
Table 3. Percentage Increase in the Rate of Major Coronary Events per Gray, 
According to Time since Radiotherapy.
Time since 
Radiotherapy*
No. of  
Case Patients
No. of  
Controls
Increase in Rate  
of Major Coronary 
Events (95% CI)†
% increase/Gy
0 to 4 yr 206 328 16.3 (3.0 to 64.3)
5 to 9 yr 216 296 15.5 (2.5 to 63.3)
10 to 19 yr 323 388 1.2 (−2.2 to 8.5)
≥20 yr 218 193 8.2 (0.4 to 26.6)
0 to ≥20 yr 963 1205 7.4 (2.9 to 14.5)
* The values shown are the numbers of years since the breast-cancer diagnosis. 
The median time from the breast-cancer diagnosis to the start of radiotherapy 
was 42 days.
† The percentage increase was estimated after stratification according to country, 
age at breast-cancer diagnosis, year of breast-cancer diagnosis, years from breast-
cancer diagnosis to first major coronary event (for case patients) or index date 
(for controls), and the presence or absence of a cardiac risk factor. Chi-square 
for heterogeneity = 5.2 with 3 df, P = 0.16; chi-square for trend = 1.2 with 1 df, 
P = 0.26.
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diac risk factors, both the baseline risks and the 
absolute increases in risk are higher. For exam-
ple, radiotherapy involving a mean dose of radia-
tion to the heart of 3 Gy in a 50-year-old woman 
with one or more cardiac risk factors would in-
crease her risk of death from is che mic heart 
disease before the age of 80 years from 3.4% to 
4.1% (an absolute increase of 0.7 percentage 
points), and it would increase her absolute risk 
of having an acute coronary event by the age of 
80 years by 1.7 percentage points. A mean dose 
of 10 Gy to her heart would result in radiation-
related risks that were considerably higher.
In conclusion, we found that incidental expo-
sure of the heart to radiotherapy for breast can-
cer increased the rate of major coronary events by 
7.4% per gray, with no apparent threshold. The 
percentage increase per unit increase in the mean 
dose of radiation to the heart was similar for 
women with and women without preexisting car-
diac risk factors, which indicates that the abso-
lute increases in risk for a given dose to the heart 
were larger for women with preexisting cardiac 
risk factors. Therefore, clinicians may wish to 
consider cardiac dose and cardiac risk factors as 
well as tumor control when making decisions 
about the use of radiotherapy for breast cancer.
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Figure 2. Cumulative Risks of Death from Is che mic Heart Disease and of at Least One Acute Coronary Event.
In Panel A, rates of death from is che mic heart disease and from all causes in the underlying population were as-
sumed to be equal to the most recent values available (mostly for the year 2010) for the 15 westernmost countries  
of the European Union (Table S11 in the Supplementary Appendix). In Panel B, the rates of acute coronary events in 
women in the underlying population who were younger than 50, 50 to 59, 60 to 69, and 70 to 79 years of age were 
assumed to be 6 times, 5 times, 3 times, and 2 times the rate of death from is che mic heart disease, respectively. In 
both panels, results are shown for a woman who was 50 years old at the time of breast-cancer diagnosis who re-
ceived either no radiotherapy or radiotherapy with a mean dose to the heart of 3 Gy or 10 Gy. Results are shown for 
women with no cardiac risk factors and for those with one or more cardiac risk factors. In both panels, the distribu-
tion of cardiac risk factors in the population was assumed to be equal to that in the present study. Cumulative risks 
for other mean doses of radiation to the heart and for different ages at irradiation are provided in Tables S12 and S13 
in the Supplementary Appendix. Acute coronary events are nonfatal or fatal major coronary events or unstable angina.
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